Berdazimer Topical Gel, 10.3%: First Approval
This article summarizes the milestones in the development of berdazimer topical gel, 10.3% leading t o this first approval for the treatment of MC. (Source: Drugs)
Source: Drugs - February 27, 2024 Category: Drugs & Pharmacology Source Type: research
Nirogacestat: First Approval
This article summarizes the milestones in the development of nirogacestat leading to this first approval for the systemic treatment of desmoid tumours. (Source: Drugs)
Source: Drugs - February 27, 2024 Category: Drugs & Pharmacology Source Type: research
Capivasertib: First Approval
This article summarizes the milestones in the development of capivasertib leading to this first approval for HR-positive, HER2-negative, locally advanced or metastatic breast cancer. (Source: Drugs)
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Lebrikizumab: First Approval
This article summarizes the milestones in the development of lebrikizumab leading to this first approval for AD. (Source: Drugs)
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Tirzepatide: A Review in Type 2 Diabetes
In conclusion, tirzepatide i s a valuable addition to the treatment options for T2DM. (Source: Drugs)
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Etrasimod: First Approval
This article summarises the milestones in the development of etrasimod leading to this first approval for the treatment of ulcer ative colitis in adults. (Source: Drugs)
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Vonoprazan: A Review in Helicobacter pylori Infection
AbstractTreatment for the eradication ofHelicobacter pylori infection, a leading cause of peptic ulcer disease and an important risk factor for gastric cancer and mucosa-associated lymphoid tissue lymphoma, is indicated whenever infection is identified. However, treatment success rates with current guideline-recommended proton-pump inhibitor (PPI)-based regimens remain suboptimal, with one potential factor associated with treatment failure being inadequate acid suppression. Vonoprazan (Voquezna®) is a first-in-class potassium-competitive acid blocker with the potential to provide potent and sustained acid suppression. Fol...
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Capivasertib: First Approval
This article summarizes the milestones in the development of capivasertib leading to this first approval for HR-positive, HER2-negative, locally advanced or metastatic breast cancer. (Source: Drugs)
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Lebrikizumab: First Approval
This article summarizes the milestones in the development of lebrikizumab leading to this first approval for AD. (Source: Drugs)
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Tirzepatide: A Review in Type 2 Diabetes
In conclusion, tirzepatide i s a valuable addition to the treatment options for T2DM. (Source: Drugs)
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Etrasimod: First Approval
This article summarises the milestones in the development of etrasimod leading to this first approval for the treatment of ulcer ative colitis in adults. (Source: Drugs)
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Vonoprazan: A Review in Helicobacter pylori Infection
AbstractTreatment for the eradication ofHelicobacter pylori infection, a leading cause of peptic ulcer disease and an important risk factor for gastric cancer and mucosa-associated lymphoid tissue lymphoma, is indicated whenever infection is identified. However, treatment success rates with current guideline-recommended proton-pump inhibitor (PPI)-based regimens remain suboptimal, with one potential factor associated with treatment failure being inadequate acid suppression. Vonoprazan (Voquezna®) is a first-in-class potassium-competitive acid blocker with the potential to provide potent and sustained acid suppression. Fol...
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression
(Source: Drugs)
Source: Drugs - February 12, 2024 Category: Drugs & Pharmacology Source Type: research
Methadone for Cancer Pain Management in Children: A Review of Literature
AbstractPain associated with cancer is a common feature among children and adolescents. Among opioids, methadone is a unique drug for its multiple mechanisms of action. Methadone is currently underutilized in children. The use of methadone for cancer pain management in children was assessed in a systematic review. Altogether, 141 children receiving methadone were examined, and another 126 children were assessed for QT prolongation. In the clinical studies, modalities of use, dosing, and duration of assessment were highly variable. In general, methadone was effective and well tolerated with a limited tendency for dose incre...
Source: Drugs - February 7, 2024 Category: Drugs & Pharmacology Source Type: research
